Immunicon — Investor Presentation (June 2005)
29 slides from Immunicon's investor presentation, Jun 6, 2005
Slide 1: Link to searchable text of Slide
Link to searchable text of Slide
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements that reflect management’s current views and opinions as to the status of the Company’s products, clinical trials, regulatory approval process, product development, research programs and other future events and operat
Slide 3: Section 1: Company Overview
SECTION 1 Company Overview
Slide 4: Circulating Tumor Cells (CTCs) in Cancer Diagnostics
Circulating Tumor Cells (CTCs) in Cancer Diagnostics ABC World News Tonight 8/18/04 © IMMUNICON
Slide 5: Company Overview
Company Overview Immunicon develops and is commercializing products for cell and molecular analysis with an initial focus in cancer: ¢ All FDA clearances for initial products received ¢ Invitro diagnostic commercialization in progress ¢ Strategic alliance with J&J in cancer « Large market opportunit
Slide 6: A Systems Approach to Rare Cell Analysis
A Systems Approach to Rare Cell Analysis Kits and Reagents Cell Analysis Marker Reagents Enrichment Kits for Counting for Characterization Kits for MDx Sample Standardized } Preservation Processing Analysis /cellsave Hcelltracks "celltracks ‘Preservative tube anabyzer Tt Off-Line Molecular and Prote
Slide 7: Section: Technology and Products
SECTION 2 Technology and Products
Slide 8: "Real-Time Biopsy" Using a Blood Sample
“Real-Time Biopsy” Using a Blood Sample Circulating Tumor Cells (CTCs) and Associated Markers: Assess Prognosis Count ‘mmm Direct Therapy Monitor Disease Phenotype mmm Diagnose Stumorcetl) & Genotype Specify Therapy entering cire Determine Risk Assessment Presence ad for Cancer Most tumors are of ep
Slide 9: CellTracks Technology
CellTracks® Technology Nucleic Acid/Protein Analyses conlses rch Kits & Markers. 4cellspotter Acelitracks Feelltracks © IMMUNICON
Slide 10: A New Paradigm for Cancer Disease Management
A New Paradigm for Cancer Disease Management Current standard: Potential future standard: Radiologist measures changes in Number and/or makeup of CTCs better lesions on a CT scan to assess reflects efficacy of treatment tumor burden increase/decrease Subjective and semi-quantitative | Objective and
Slide 11: NEJM 8/19/04: CTCs Predict Survival
NEJM 8/19/04: | CTCs Predict Survival %Probability of Survival Before initiation of therapy >18 months >5 CTCs (N=87) N=177 Logrank < 0.0001 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 Time from start of therapy (Weeks) © IMMUNICON
Slide 12: NEJM 8/19/04: CTCs Predict Survival at 1st Follow-Up
NEJM 8/19/04: CTCs Predict Survival at 1‘t Follow-Up %Probability of Survival 100% 90% 80% 70% + 60% + 50% 40% 30% 20% + 10% 4 ~4 weeks after initiation of therapy <5 CTCs (N=114) >18 Months 7.0 months : H >5CTCs (N=49) N=163 0 H Logrank a 0. 0001 5 1015 20 2 30 35 40 6 50 35 60 65 70 15 80 Time fro
Slide 13: Proven Clinical Utility
Proven Clinical Utility >Current measures to determine if therapy is effective are inadequate >CTCs are an independent prognostic indicator of favorable & unfavorable outcomes (PFS and OS) >When elevated, CTCs predict short PFS and OS and may indicate patient is on a futile therapy P @ IMMUNICON
Slide 14: New FDA Classification
New FDA Classification Classification received through “de novo” process: Simplifies/shortens regulatory timelines (510(k) process) Written into Code of Federal Regulations (866.6020) « FDA “special controls” guidance document issued ¢@ Creates a significant barrier to entry oe FDA cleared labeling:
Slide 15: "Real-Time Biopsy" from a Blood Sample
“Real-Time Biopsy” from a Blood Sample Enables selection of targeted therapies Taxol Herceptin 225 2 eae a oO 175 E 150 8 ios | BE oite2ss+ OD Hera ++ = 100 2 75 ‘tee+ Gh nere- ts) o 8 5 25 0 B = = 012 3 4 5 6 7 8 9 1011 12 13 14 15 16 17 18 19 20 Time (weeks) > IntJOncol 21: 1111-1116, 2002 ‘ @ IMM
Slide 16: Current clinical development status
Current clinical development status ¢Breast Cancer - “Bone only” disease data positive —CTCs predict outcome during therapy —CTCs a better predictor of outcome than imaging ¢Colorectal Cancer — Planned interim analysis encouraging — ~400 patient labeling study in progress (>60% enrolled) Prostate Ca
Slide 17: Many Product Opportunities
Many Product Opportunities ¢ Potential follow-on CTC applications —Other settings in cancer (diagnosis, recurrence monitoring...) —RNA/DNA assays and protein markers —Bone marrow assay ¢ Potential Circulating Endothelial Cells (CECs) applications ~ Cancer (angiogenesis, monitoring toxicity,...) —Car
Slide 18: Section: Commercialization
SECTION 3 Commercialization
Slide 19: Significant Market Opportunity
Significant Market Opportunity Overall U.S. Market «Cancer is the second leading killer —Prevalence: 9.8 million survivors —Incidence: 1.37 million new diagnoses p.a. Mortality: 570,280 deaths p.a. #~86% of all cancers are carcinomas (solid tumors) —CellSearch™ System is “pan-carcinoma” Cancer Facts
Slide 20: Significant Potential Market Opportunity
Significant Potential Market Opportunity Cancer Metastatic Pool Breast 78,809 Colorectal 71,136 Prostate 60,449 Other Carcinomas* 304,462 Total 514,856 * Includes melanoma Derived from Cancer Facts and Figures 2004, American Cancer Society © IMMUNICON
Slide 21: Strategic Alliance in Cancer with Johnson & Johnson
Strategic Alliance in Cancer with Johnson & Johnson Key elements: ¢ Immunicon develops and manufactures @ J&d finishes, sells and services « Revenue shared (~30% to IMMC on reagents) # Access to J&J technology, expertise and distribution @ Large equity investment by J&J Development Corp. ¢ Veridex,
Slide 22: Sales and Marketing Strategy
Sales and Marketing Strategy | VeEripex wet SIRI Surgeons Pathologists Oncologists ‘i © IMMUNICON
Slide 23: Section: Financial Overview and Milestones
SECTION 4 Financial Overview and Milestones
Slide 24: Business Model
Business Model Attractive economics ¢ List price for instrument system = $120,000 ¢ List price to lab for CTC test = $175.00 ¢ Fast payback for the hospital/reference lab ¢ High revenue/margins for J&J and Immunicon ¢ Cost effective for the patient/healthcare system Key drivers for reimbursement ¢ J
Slide 25: Financial Summary (quarter ended 3/31/05)
Financial Summary (quarter ended 3/31/05) ¢Commercialization status: #26 AutoPreps and 25 CellSpotters shipped # Systems in the USA, Europe and Japan «Systems with reference labs, hospitals, CRO, major Pharma ¢ Quest Diagnostics (USA) and SRL (Japan) «Reference labs are multi-placement opportunities
Slide 26: Milestones Achieved
Milestones Achieved + ° ° ° ° ° ° ° Publication in New England Journal of Medicine —_Q3/04 U.S. in vitro diagnostic (IVD) launch Q3/04 Announced deal with Quest Diagnostics Q3/04 Shipped units to Europe and Japan (RUO) Q2&Q3/04 Positive data in “bone only” breast cancer Q4/04 Positive interim data i
Slide 27: Near-term Milestones
Near-term Milestones ¢ Launch CellTracks Analyzer II Q2/05 ¢ Circulating Endothelial Cells (CECs) — Clinical research studies In progress — RUO commercialization In progress ¢ 510(k) for new data in breast cancer H2/05 ¢ San Antonio Breast Cancer Symposium Q4/05 ¢ Bone marrow assay (RUO) Q1/2006 ¢ C
Slide 28: Investment Highlights
Investment Highlights ¢ Address unmet medical needs in large markets, starting with cancer ¢ Strategic partnership in cancer with J&J « Commercialization process well underway — Compelling clinical data ~ FDA clearances received/passed inspection — ISO 13485:2003 certification received — J&J executi
Slide 29: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements that reflect management’s current views and opinions as to the status of the Company’s products, clinical trials, regulatory approval process, product development, research programs and other future events and operat